71. Serafini PC, Catalino J, Lobo RA. The effect of spironolactone on genital skin 5 alpha-reductase activity. *J Steroid Biochem.* 1985; 23:191–4.
72. Shaw JC. Spironolactone in dermatologic therapy. *J Am Acad Dermatol.* 1991;24:236–43.
73. Helfer EL, Miller JL, Rose LI. Side-effects of spironolactone therapy in the hirsute woman. *J Clin Endocrinol Metab.* 1988;66:208–11.
74. Ponjee GA, de RHA, Vader HL. Androstanediolglucuronide: a parameter for peripheral androgen activity before and during therapy with cyproterone acetate. *Acta Endocrinol (Copenh).* 1991;124:411–6.
75. Vermeulen A, Rubens R. Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women. *Contraception.* 1988;38:419–28.
76. Prelevic GM, Puzigaca Z, Balint-Peric LA. Effects of an oral contraceptive containing cyproterone acetate (Diane-35) on the symptoms, hormone profile, and ovarian volume of hirsute women with polycystic ovarian syndrome. *Ann N Y Acad Sci.* 1993;687:255–62.
77. Vincens M, Mercier-Bodard C, Mowszowicz I, Kuttann F, Mauvais-Jarvis P. Testosterone–estradiol binding globulin (TeBG) in hirsute patients treated with cyproterone acetate (CPA) and percutaneous estradiol. *J Steroid Biochem.* 1989;33:531–4.
78. Hammerstein J, Meckies J, Leo-Rossberg I, Moltz L, Zielske F. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. *J Steroid Biochem.* 1975;6:827–36.
79. Lissak A, Sorokin Y, Calderon I, Dirnfeld M, Lioz H, Abramovici H. Treatment of hirsutism with cimetidine: a prospective randomized controlled trial. *Fertil Steril.* 1989;51:247–50.
80. Golditch IM, Price VH. Treatment of hirsutism with cimetidine. *Obstet Gynecol.* 1990;75:911–3.
81. Vigersky RA, Mehlman I, Glass AR, Smith CE. Treatment of hirsute women with cimetidine. *N Engl J Med.* 1980;303:1042.
82. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess [Comment in: *N Engl J Med.* 1992;327:194–6.] *N Engl J Med.* 1992;327:157–62.
83. Cusan L, Dupont A, Belanger A, Tremblay RR, Manhes G, Labrie F. Treatment of hirsutism with the pure antiandrogen flutamide. *J Am Acad Dermatol.* 1990;23:462–9.
84. Couzinet B, Pholsena M, Young J, Schaison G. The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. *Clin Endocrinol (Oxf).* 1993;39:157–62.
85. Tremblay RR. Compromise in the treatment of hirsutism with flutamide. *In Vivo.* 1993;7:549–51.
86. Fruzzetti F, De LD, Ricci C, Fioretti P. Clinical and endocrine effects of flutamide in hyperandrogenic women. *Fertil Steril.* 1993;60:806–13.
87. Erenus M, Gurbuz O, Durmusoglu F, Demircay Z, Pekin S. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. *Fertil Steril.* 1994;61:613–6.
88. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. *Fertil Steril.* 1994;61:281–7.
89. Wysowski DK, Freiman JP, Tourtelot JB, Horton ML 3d. Fatal and nonfatal hepatotoxicity associated with flutamide. *Ann Intern Med.* 1993;118:860–4.
90. Lynfield YL, Macwilliams P. Shaving and hair growth. *J Invest Dermatol.* 1970;55:170–2.
91. Richards RN, Uy M, Meharg G. Temporary hair removal in patients with hirsutism: a clinical study. *Cutis.* 1990;45:199–202.

REFLECTIONS

... the department of witchcraft called medical science. GEORGE BERNARD SHAW, *The Philanderer*